Skip to main content
MAYNE PHARMA GROUP LIMITED logo

MAYNE PHARMA GROUP LIMITED — Investor Relations & Filings

Ticker · MYX ISIN · AU000000MYX0 LEI · 549300VIRDEN0N4MJG59 ASX Manufacturing
Open in API
Filings indexed 1,121 across all filing types
Latest filing 2012-12-18 Director's Dealing
Country AU Australia
Listing ASX MYX

About MAYNE PHARMA GROUP LIMITED

https://www.maynepharma.com

Mayne Pharma Group Limited is a specialty pharmaceutical company focused on the development and commercialization of branded and generic medicines. The company operates through specialized segments including Women's Health and Dermatology. Its Women's Health portfolio features innovative contraceptive solutions, while the Dermatology division provides a broad range of treatments for various skin conditions. Beyond its product portfolio, the company provides contract development and manufacturing services (CDMO), leveraging proprietary drug delivery technologies to produce complex oral and topical dosage forms. The organization focuses on high-growth specialty markets, aiming to deliver differentiated therapeutic options and improve patient outcomes through technical excellence and strategic commercialization.

Recent filings

Filing Released Lang Actions
Change of Director's Interest Notice x 3 6 pages 46.5KB
Director's Dealing Classification · 100% confidence The document is titled 'Appendix 3Y Change of Director’s Interest Notice' and references ASX listing rule 3.19A.2 and section 205G of the Corporations Act. It details changes in securities holdings by company directors, including the nature of the interest, number of securities acquired or disposed, and the value of transactions. The document is a formal notification of personal share transactions by company directors. This matches the definition of 'Director's Dealing' filings, which report personal share transactions by company directors and executives (insider trades). The document is about changes in director interests, not about financial results, governance, or other categories. The length and content confirm it is a full notice of director dealings, not a brief announcement or a report publication announcement.
2012-12-18 English
Completion of placement 1 page 91.7KB
Capital/Financing Update Classification · 100% confidence The document is a short announcement dated 17 December 2012 from Mayne Pharma Group Limited regarding the successful completion of a placement of approximately 61 million shares to raise gross proceeds of A$18.0 million. It discusses the book build, settlement dates, and plans for a share purchase plan. There is no financial data, detailed financial statements, or comprehensive report content. The document is clearly an update on a capital raising activity, specifically a placement of shares, which fits the Capital/Financing Update category. The document length is short (2156 characters), and it is not a report or a regulatory filing but an announcement of a financing event. Therefore, the appropriate classification is Capital/Financing Update (CAP).
2012-12-16 English
Trading Halt 1 page 77.3KB
Regulatory Filings Classification · 95% confidence The document is a market release announcing a trading halt for Mayne Pharma Group Limited securities pending a forthcoming announcement. It does not contain financial data, report content, or detailed information about the company’s financials or management. It is a regulatory announcement related to trading status rather than a report or detailed filing. Therefore, it fits best under Regulatory Filings (RNS). The document length is short and it is an announcement, not a report itself.
2012-12-13 English
Request for Trading Halt 1 page 45.6KB
Capital/Financing Update Classification · 95% confidence The document is a letter from Mayne Pharma Group Limited to the ASX requesting a trading halt. It mentions the purpose is to announce an institutional placement to fund an acquisition. The document is short (1140 characters) and is a formal request for a trading halt, not a report or announcement of financial results. It does not contain financial data or detailed report content. This fits the category of Capital/Financing Update (CAP), as it relates to fundraising activities and capital structure changes.
2012-12-13 English
Mayne Pharma announces the acquisition of Kapanol 3 pages 91.4KB
Capital/Financing Update Classification · 95% confidence The document is a detailed announcement about Mayne Pharma's acquisition of Kapanol in Australia, including financial terms, funding via an equity placement, and a share purchase plan. It discusses the acquisition deal, expected financial impact, and capital raising activities. There are no financial statements or comprehensive financial performance data typical of an Annual Report or Interim Report. The focus is on the acquisition transaction and related financing. This fits the definition of a Capital/Financing Update (CAP), as it provides updates on company fundraising and capital structure changes related to the acquisition.
2012-12-13 English
Investor Presentation Acquisition of Kapanol 13 pages 626.7KB
Investor Presentation Classification · 95% confidence The document is a detailed presentation by Mayne Pharma Group Limited regarding the acquisition of Kapanol®. It includes transaction overview, market overview, strategic rationale, and financial considerations related to the acquisition. The text explicitly states it is a presentation and includes disclaimers typical of investor presentations. There is no indication that this is a regulatory filing, earnings release, or annual report. The content focuses on the acquisition and financing details, market data, and strategic rationale, which aligns with an investor presentation. Therefore, the document fits best under the category 'Investor Presentation' (IP). The document length (15,000 characters) and detailed content support this classification with high confidence.
2012-12-13 English

Browse filings by year

20 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.